TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06222567

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 15 minutes pumping with INITIATE program
Description: 15 minutes pumping with INITIATE program
Study: NCT04753723

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Gentamycin with Platform Wound Device
Description: Treatment of wounds with gentamycin and covered with platform wound device.
Study: NCT05523804

Intervention type: PROCEDURE
Intervention: interval cytoreductive surgery
Description: cytoreductive surgery after 3-4 cycles of chemotherapy

Intervention type: PROCEDURE
Intervention: delayed cytoreductive surgery
Description: surgery after \>5 cycles of chemotherapy

Intervention type: OTHER
Intervention: no surgery
Description: no cytoreductive surgery (\>5 cycles of chemotherapy alone)
Study: NCT05059847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Training routine assigned by randomized chart

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: Training routine assigned by randomized chart
Study: NCT04992377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-EPOCH in Combination With Ibrutinib
Description: Induction:~(21-day per cycle) Ibrutinib:420mg given orally , once daily.~Details of R-DA-EPOCH are as follows:~Rituximab: 375 mg/m2 given intravenously (IV) on day 0 Etoposide: 50 mg/m2 given CIV from day 1-4 Doxorubicin: 10 mg/m2 given CIV from day 1-4 Vincristine: 0.4 mg/m2 given CIV from day 1-4 Cyclophosphamide: 750 mg/m2/day IV on day 5 Prednisone: 60 mg/m2 given orally bid on days 1-5. Patients who achieve CR after 4 cycles enter the consolidation treatment ; Patients with PR after 4 cycles would receive another 2 cycles of R-EPOCH + ibrutinib induction therapy, they could enter the consolidation treatment if they achieve CR ,withdrawn from the study if they achieve ≤ PR; Patients with SD/PD after 4 cycles of treatment are withdrawn from the study.~Consolidation:~2 cycles of R-EPOCH + Ibrutinib (dose as before) treatment~Maintenance:~Ibrutinib 420 mg/day for 24 months or until disease progression or intolerable toxicity
Study: NCT05381675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-rehabillitation
Description: Tele-rehabilitation program will be performed by physiotherapist two times a week for six consecutive weeks. Program including the following exercises:~Breathing exercises Aerobic exercises Flexibility Strengthening exercises

Intervention type: OTHER
Group type: OTHER
Intervention: Prescribed Exercise Program
Description: The prescribed exercise program will be performed two times a week for six consecutive weeks. Program including the following exercises:~Breathing exercises Aerobic exercises Flexibility Strengthening exercises
Study: NCT05452824

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi Prehabilitation
Description: The intervention arm will be oriented to a WaQi (youthful vitality) program 8 weeks prior to their scheduled surgery date. The WaQi program uses a Tai Chi curriculum previously successfully implemented in older adults, and at the Memorial Sloan Kettering Cancer Center (MSKCC). It has an online teaching module and is uniquely suited for our study population. The program requires no difficult movement transitions, but still contains all essential parts including meditation. The WaQi program has less psychological stress and physical challenge than other exercise activities because it can be performed either sitting or standing. Intervention participants will also receive printed materials from Prostate Cancer Canada about prostate cancer management. These materials include information about how to cope with prostate cancer including pelvic floor exercise, physical activity, healthy eating, and mental wellbeing.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Control arm participants will receive printed materials identical to intervention arm participants with general information on a healthy lifestyle. The control arm will receive an 8-week online Tai Chi teaching module subscription at the end of the study.
Study: NCT05210621

Intervention type: DRUG
Group type: OTHER
Intervention: Ocrelizumab
Description: ocrelizumab will be administered as single 600-mg infusions in 500 mL 0.9% sodium chloride every 24 weeks (±14 days) up to Week 192 (Year 4) of this study
Study: NCT05152667

Intervention type: DEVICE
Intervention: levonorgestrel-releasing intrauterine device (LNG-IUS)
Description: Intervention is administered proceeding the ICSI
Study: NCT04735861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg iv. q3w, up to 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Biosimilar IBI305
Description: Bevacizumab 15mg/kg iv. q3w, up to 22 cycles
Study: NCT04555720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdisciplinary Visit
Description: If assigned to the interdisciplinary group, participants will see social work, physical therapy, occupational therapy, speech therapy, and pharmacy in a scheduled rotation for about 45 minutes each. After these evaluations, the team meets with the participants doctor for a discussion of treatment. After this meeting, the participants doctor will meet to discuss a treatment plan and make recommendations.
Study: NCT05396378

Intervention type: DIETARY_SUPPLEMENT
Intervention: Oral glucose in liquid form
Description: A glucose containing drink that has a fixed dose of 25 g of glucose per can.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Oral glucose in liquid form
Description: A glucose containing drink that has a fixed dose of 25 g of glucose per can.
Study: NCT06222567

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5 minutes extra pumping with MAINTAIN program
Description: Additional 5 minutes extra pumping with MAINTAIN program
Study: NCT05254951

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tidal Volume Challenge
Description: Tidal Volume Challenge to predict fluid responsiveness with stroke volume variation and pulse pressure variation
Study: NCT06006065

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Upper limb somatosensory discrimination therapy
Description: Participants will receive three 45 minute sessions of upper limb somatosensory discrimination therapy per week for a period of 8 weeks.~Each session includes 30 minutes of component-based training, including graded practice of three components of somatosensation (i.e., tactile object recognition, texture discrimination and proprioception). Next, 15 minutes of occupation-based practice will be completed to enhance transfer to a functional context. This includes repetitive and structured practice of self-chosen activities of daily living, while attention is designated to the somatosensory aspects necessary for successful task completion (e.g., identification of button based on touch).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Upper limb motor therapy
Description: Participants in the control group will receive an equal amount of motor training, including 30 minutes of unimanual motor tasks and 15 minutes of bimanual goal directed training. The unimanual motor tasks will be selected based on the main difficulties of the child (e.g., grip strength, supination). Bimanual goal directed training includes whole task practice of self-chosen activities of daily living. All therapy sessions will be performed under supervision of a trained physical and/or occupational therapist. Therapy adherence and progression will be closely monitored by the therapist.
Study: NCT05046873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL
Description: Participants will receive a subcutaneus (s.c) co-formulation injection of 0.5 mg semaglutide and 5 mg NNC0480-0389 together with a subcutaneus injection (s.c) of semaglutide(placebo)on two separate dosing visits separated by at least 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide 1.34 mg/mL (placebo)
Description: Participants will receive a subcutaneus (s.c) co-formulation injection of 0.5 mg semaglutide and 5 mg NNC0480-0389 together with a subcutaneus injection (s.c) of semaglutide(placebo)on two separate dosing visits separated by at least 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide 1.34 mg/mL
Description: The participants will be receive a subcutaneus (s.c) injection of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate doing visits separated by at least 8 weeks.
Study: NCT06439017

Intervention type: OTHER
Intervention: Questionaire
Description: The study will involve completing the Mind Excessively Wandering Scale (MEWS) and World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0), a 36-item self-administered questionnaire.

Intervention type: OTHER
Intervention: Questionaire
Description: The study will involve completing the Mind Excessively Wandering Scale (MEWS) and World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0), a 36-item self-administered questionnaire.
Study: NCT05753410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Courage
Description: Self-guided online intervention
Study: NCT04838275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week mHealth home exercise prescription
Description: 3x/week home walking protocol, 2x/week resistance exercise program
Study: NCT05046873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NNC0480-0389 A 10 mg/mL
Description: The participants will be receive a subcutaneus (s.c) injection of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate doing visits separated by at least 8 weeks.
Study: NCT06018207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam oral solution
Description: The ED50 dose of midazolam oral solution for hypnosis is studied using an up-and-down sequential allocation while waiting for surgery and general anesthesia in preoperative room.~The starting dose is 6 mg and the step size is 1 mg. The interval sequential dose is varied by 1 mg based on the hypnosis response of the previous patient after one hour.~Definition of successful hypnosis by taking midazolam oral solution:~The polysomnograph (PSG) not only shows stage N2 within 30 minutes, but also shows stage N3 within an hour; or else, definition of unsuccessful hypnosis.~The procedure is as follows: (1) The first subject is given 6mg of midazolam oral solution; (2) If succeed, the second subject takes 4mg; (3) If not succeed, the second subject takes 8mg; (4) Until seven sequence reversal inflection points.
Study: NCT05729555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compound ibuprofen polyrelease tablets
Description: Specification: Each tablet containing ibuprofen 400 mg, diphenhydramine hydrochloride 50 mg Batch number: 22082801 Content: Ibuprofen 96.9%, diphenhydramine hydrochloride 102.4% Effective: August 27,2024 S torage conditions: sealed, room temperature. Manufacturers: Overseas Pharmaceuticals, Ltd. Usage and dosage：Once a day, one tablet at a time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reference 1 (R1): Ibuprofen Tablets (Motrin IB®)reference 2 (R2): Diphenhydramine Hydrochloride Tablets (Benadryl®)
Description: Specification: 200 mg Batch number: 2CE2330 Content: 100.5% Expiry date: December 2023 Storage conditions; Storage in 20℃ -25℃ manufacturer: JOHNSON \& JOHNSON CONSUMER INC. Usage and dosage：Once a day, two tablets at a time~Specification: 25 mg Batch number: BCC009 Content: 99.2% Effective to: December 2023 storage conditions; storage at 20℃ -25℃, shading manufacturer: JOHNSON \& JOHNSON CONSUMER INC Usage and dosage：Once a day, two tablets at a time
Study: NCT05657938

Intervention type: DEVICE
Intervention: Wearable Device
Description: The wearable device used in this study is an FDA 510(k) cleared Class II medical device designed to collect medical grade, clinical quality biometric, physiological and other electronic clinician outcome assessments data in a clinical trial setting. The system processes raw data into recognizable clinical metrics including vital signs, activity and posture classifications, surface electromyography (sEMG), and sleep metrics. The sensors are multi-modal, multilocation, rechargeable and reusable.

Intervention type: DEVICE
Intervention: Wearable Device
Description: The wearable device used in this study is an FDA 510(k) cleared Class II medical device designed to collect medical grade, clinical quality biometric, physiological and other electronic clinician outcome assessments data in a clinical trial setting. The system processes raw data into recognizable clinical metrics including vital signs, activity and posture classifications, surface electromyography (sEMG), and sleep metrics. The sensors are multi-modal, multilocation, rechargeable and reusable.

Intervention type: OTHER
Intervention: Duchenne Video Assessment (DVA)
Description: The DVA is a standardized tool that documents and assesses compensatory movement strategies as a marker of quality of movement.
Study: NCT05375162

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Core Intervention
Description: All participants will receive a low-resource self-monitoring intervention consisting of the Fitbit Alta HR (or similar) and the Opt2Move self-monitoring app.~Participants will be provided with the Fitbit Alta HR. They will be asked to download the Fitbit app and wear the Fitbit 24/7 throughout the 24-week study period. The Fitbit measures PA intensity, steps, and heart rate, and it syncs directly with the Ftibit app on the smartphone which will ill automatically sync with the Opt2Move study app and provide Fitbit data to the study team in real-time.~The core Opt2Move study app will support YACS to increase their MVPA. The app will also contain educational information on MVPA and effective behavior change strategies for building self-efficacy, overcoming barriers, enhancing facilitators, setting realistic outcome expectations, and self-regulatory skill-building (i.e., reviewing progress, goal setting, action-planning and coping with disruptions).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Core Intervention
Description: All participants will receive a low-resource self-monitoring intervention consisting of the Fitbit Alta HR (or similar) and the Opt2Move self-monitoring app.~Participants will be provided with the Fitbit Alta HR. They will be asked to download the Fitbit app and wear the Fitbit 24/7 throughout the 24-week study period. The Fitbit measures PA intensity, steps, and heart rate, and it syncs directly with the Ftibit app on the smartphone which will ill automatically sync with the Opt2Move study app and provide Fitbit data to the study team in real-time.~The core Opt2Move study app will support YACS to increase their MVPA. The app will also contain educational information on MVPA and effective behavior change strategies for building self-efficacy, overcoming barriers, enhancing facilitators, setting realistic outcome expectations, and self-regulatory skill-building (i.e., reviewing progress, goal setting, action-planning and coping with disruptions).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-Coach
Description: Participants assigned to this condition will receive a weekly scheduled text message from their coach. Text messages will focus on building self-efficacy and self-regulation skills, setting realistic outcome expectations, overcoming barriers, and problem-solving and will directly support the participant's engagement in the intervention. The coach will provide a brief overview of the participant's recent progress and goals, ask if they are having any barriers and help them troubleshoot and set specific goals for the next week. Text message protocols will be informed by the investigators' previous experience using telephone coaching to promote MVPA in cancer survivors. In addition to the scheduled messaging, participants will also be instructed to reach out to their coach with any questions or for additional assistance.
Study: NCT05657938

Intervention type: OTHER
Intervention: Duchenne Video Assessment (DVA)
Description: The DVA is a standardized tool that documents and assesses compensatory movement strategies as a marker of quality of movement.
Study: NCT06055985

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will receive placebo orally administered as tablet at pre-specified time points during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB0022
Description: Study participants will receive UCB0022 dose A or B orally administered as tablet at pre-specified time points during the Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB0022
Description: Study participants will receive UCB0022 dose A or B orally administered as tablet at pre-specified time points during the Treatment Period.
Study: NCT06306755

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Risk Assessment and Individualized Surveillance
Description: 1. An epidemiological questionnaire-based risk assessment for UGIC conducted prior to the endoscopic examination;~2. Individuals identified as high-risk receive the upper gastrointestinal endoscopic examination with Lugol's Iodine in the esophagus and indigo carmine staining in the stomach;~3. Individualized reexamination and surveillance strategy will be given to participants diagnosed with premalignant lesions, based on evaluation of risk progression using endoscopic characteristics, pathological diagnosis, and biomarkers.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Universal screening
Description: 1. A questionnaire investigation;~2. All participants undergo the upper gastrointestinal endoscopic examination with Lugol's Iodine in the esophagus and indigo carmine staining in the stomach;~3. Reexamination and surveillance will be performed according to the current guidelines for UGIC screening and clinical treatment.
Study: NCT05929079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retatrutide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retatrutide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retatrutide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT05375162

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: E-Coach
Description: Participants assigned to this condition will receive a weekly scheduled text message from their coach. Text messages will focus on building self-efficacy and self-regulation skills, setting realistic outcome expectations, overcoming barriers, and problem-solving and will directly support the participant's engagement in the intervention. The coach will provide a brief overview of the participant's recent progress and goals, ask if they are having any barriers and help them troubleshoot and set specific goals for the next week. Text message protocols will be informed by the investigators' previous experience using telephone coaching to promote MVPA in cancer survivors. In addition to the scheduled messaging, participants will also be instructed to reach out to their coach with any questions or for additional assistance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: E-Coach
Description: Participants assigned to this condition will receive a weekly scheduled text message from their coach. Text messages will focus on building self-efficacy and self-regulation skills, setting realistic outcome expectations, overcoming barriers, and problem-solving and will directly support the participant's engagement in the intervention. The coach will provide a brief overview of the participant's recent progress and goals, ask if they are having any barriers and help them troubleshoot and set specific goals for the next week. Text message protocols will be informed by the investigators' previous experience using telephone coaching to promote MVPA in cancer survivors. In addition to the scheduled messaging, participants will also be instructed to reach out to their coach with any questions or for additional assistance.
Study: NCT05613205

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TYP04A Low Dose without Alum investigational vaccine
Description: 2 doses of TYP04A Low Dose without Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TYP04B Full Dose without Alum investigational vaccine
Description: 2 doses of TYP04B Full Dose without Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.
Study: NCT05613205

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TYP03A Low Dose with Alum investigational vaccine
Description: 2 doses of TYP03A Low Dose with Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TYP03B Full Dose with Alum investigational vaccine
Description: 2 doses of TYP03B Full Dose with Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sanofi Pasteur's Typhoid Vi polysaccharide vaccine
Description: 1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly, at Day 1, to participants in the control group.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine
Description: 1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine administered intramuscularly, at Day 169, to participants in the control group.
Study: NCT04984837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacutamab
Description: 750 mg/IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m²

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatine
Description: 100 mg/m²

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatine
Description: 100 mg/m²
Study: NCT04832360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: Financial incentives may be offered to participants based on their behavioral outcomes (smoking cessation and participation in online psychoeducation about smoking)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: Financial incentives may be offered to participants based on their behavioral outcomes (smoking cessation and participation in online psychoeducation about smoking)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: Financial incentives may be offered to participants based on their behavioral outcomes (smoking cessation and participation in online psychoeducation about smoking)